Adeyemo shares what you need to know when you miss your GLP-1 medication: What happens when you stop taking GLP-1 receptor agonists
Book your B12 shot today
Removal of Two Social Drivers of Health Measures From the Hospital OQR, REHQR, and ASCQR Programs Beginning With the CY 2025 Reporting Period In the CY 2026 OPPS/ASC proposed rule (90 FR 33756), we proposed to remove two social drivers of health (SDOH) process measures from the Hospital OQR, REHQR, and ASCQR Programs beginning with the CY 2025 reporting period: Screening for Social Drivers of Health (adopted at 89 FR 94381 through 94398) and Screen Positive Rate for Social Drivers of Health (adopted at 89 FR 94398 through 94403), for which the CY 2025 reporting period would be voluntary, and mandatory reporting would begin with the CY 2026 reporting period/CY 2028 payment or program determination
Versus GLP-1 peptides GLP-1 receptor agonists like semaglutide and tirzepatide have become popular for weight loss
Key InformationHuman Use Status: Boldenone undecylenate is not approved for human use by the FDA or other regulatory bodies and has no legitimate therapeutic use in human medicine
However, it is important to note that BPC-157 is not approved by the FDA for human use and is not available as an approved treatment at reputable medical practices, including ours
